Doron Therapeutics Announces Positive End-of-Phase 2 and Initial RMAT Meeting With FDA for MOTYS (PTP-001) in the Treatment of Knee Osteoarthritis
Key Regulatory Milestone Provides Clear Development Roadmap to Registration for MOTYS Initiation of Phase 3